ISPOR 5th ASIA-PACIFIC CONFERENCE

2-4 September 2012 ▪ Taipei, Taiwan

CONFERENCE AT-A-GLANCE

SUNDAY, 2 SEPTEMBER

8:00AM-12:00PM MORNING SHORT COURSES Short Course registration required
Introduction to Pharmacoeconomics Room 201D (2nd Floor)
Introduction to Modeling Room 201F (2nd Floor)
Introduction to Retrospective Database Design and Analysis Room 201A (2nd Floor)
Introduction to Health Technology Assessment Room 201BC (2nd Floor)
Introduction to Patient-Reported Outcomes Room 103 (1st Floor)
Meta-Analysis and Systematic Literature Review Room 201E (2nd Floor)

1:00PM-5:00PM AFTERNOON SHORT COURSES Short Course registration required
Financial Impact / Cost of Illness Room 103 (1st Floor)
Statistical Considerations in Health Economic Evaluations Room 201D (2nd Floor)
Transferability of Cost-Effectiveness Data Between Countries Room 201A (2nd Floor)
Applied Modeling Room 201E (2nd Floor)
Pharmaceutical/Biotech Pricing & Reimbursement Methodologies Room 201BC (2nd Floor)
Network Meta-Analysis and Indirect Treatment Comparisons Room 201F (2nd Floor)

5:15PM-6:15PM EDUCATIONAL SYMPOSIUM Room 102 (1st Floor)
Conducting Real-World Non-Interventional Studies in Multiple Countries: Why, When and How? Sponsored by Novartis

6:30PM-7:30PM EDUCATIONAL SYMPOSIUM Room 102 (1st Floor)
Health Economics and Outcomes Research in Personalized Medicine Sponsored by Pfizer

7:45PM-8:45PM EDUCATIONAL SYMPOSIUM Room 102 (1st Floor)
Innovation: What is it, Who Should Pay and What is a Fair Price? Sponsored by GlaxoSmithKline

9:00PM-11:00PM WELCOME RECEPTION Jade (2nd Floor)
All attendees welcome!

MONDAY, 3 SEPTEMBER

8:30AM-8:30PM RESEARCH POSTERS – I Room 201 (2nd Floor)

8:30AM-9:00AM WELCOME Room 101 (1st Floor)
Chinese/English translation
Welcome from Program Committee Co-Chairs
Welcome from ISPOR Asia Consortium Executive Committee Chair
Welcome from ISPOR President
Welcome from Taipei Mayor

9:00AM-9:15AM OPENING SPEECH Room 101 (1st Floor)
Chinese/English translation
The Future of Taiwan Health Care System and Policies

9:15AM-10:45AM FIRST PLENARY SESSION Room 101 (1st Floor)
Chinese/English translation
Health Technology Assessment in the Significantly Evolving Health Care Systems in Asia

10:45AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTERS – I

11:00AM-12:00PM ISSUE PANELS & WORKSHOPS – I
IP1: How to Harmonize HTA and Value for Innovation? Room 101 (1st Floor)
W1: Using Individual Simulation to Forecast Disease Epidemiology and Burden of Illness North Lounge (3rd Floor)
W2: Integration of Survival With Quality of Life for Outcomes Research: Sharing of a Free Software Room 105 (1st Floor)

W4: Conducting Oncology Health Services Research and Comparative Effectiveness Research Using Large Claim Databases: Taiwanese and United States Experiences South Lounge (3rd Floor)

12:00PM-3:00PM LUNCH, EXHIBITS & RESEARCH POSTERS – I

12:30PM-1:30PM EDUCATIONAL SYMPOSIUM Room 101 (1st Floor)
Chinese/English translation
Clinical Endpoints: Final Versus Surrogate Endpoint - Implications and Relevance From a Payer, Physician and Patient Perspective Sponsored by Eli Lilly and Company

1:45PM-2:45PM EDUCATIONAL SYMPOSIUM Room 101 (1st Floor)
Real-World Evidence: Meeting the Challenge of Stakeholder Needs for Demonstrating Value in Asia Sponsored by IMS Health

3:00PM-4:30PM WELCOME & SECOND PLENARY SESSION Room 101 (1st Floor)
Chinese/English translation
Involving Patients & Health Care Practitioners in Health Care Decisions: Learning From Each Other

4:30PM-4:45PM BREAK, EXHIBITS & RESEARCH POSTERS – I

4:45PM-5:45PM RESEARCH PODIUMS – I

COST-EFFECTIVENESS STUDIES Room 103 (1st Floor)
CE1: The Cost-Effectiveness Analysis of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) in Taiwan

CE2: Cost-Effectiveness of the Real-World Use of Nucleic Acid Test Screening to Donated Blood for Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus: Experience From Taiwan, A Country With a High Prevalence of Hepatitis B and C Infections

CE3: Hyperbaric Oxygen Therapy for the Treatment Non-Neurological Soft Tissue Radiation Injuries: A Cost-Effectiveness Analysis

CE4: Cost-Effectiveness of Dabigatran Compared to Genotype-Guided Warfarin Dosing for Stroke Prophylaxis in Atrial Fibrillation Patients

CANCER OUTCOMES STUDIES Room 201 (2nd Floor)
CN1: Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection

CN2: How Early-Stage Non-Persistence and Non-Adherence to Adjuvant Hormonal Therapy Associated With Postmenopausal Breast Cancer Mortality in Taiwan

CN3: Cost-Effectiveness Analysis of Treatments in Adult Cancer Patients With Low Risk Febrile Neutropenia in Thailand

CN4: Inpatient Treatment Patterns and Healthcare Expenditures for Hepatosplenic Carcinoma Among Population With Urban Basic Health Insurance in China

DIABETES OUTCOMES STUDIES Room 105 (1st Floor)
DB1: Epidemiology, Treatment and Economic Burden of Type 2 Diabetes Mellitus With Nephropathy Complications in China

DB2: Vitamin D Deficiency and Diabetes: Perceptions of Pharmacists and Physicians

DB3: Indirect Treatment Comparison (ITC) or Cost Effectiveness Analysis (CEA): A Study

DB4: Screening for Diabetic Retinopathy in Hong Kong: Is Inverse Care Law Operating?

HEALTH CARE USE AND POLICY STUDIES Room 101 (1st Floor)
HC1: Price Premium for Innovation? Cost Calculation Method in Japan vs. Cost Utility Analysis in South Korea

HC2: A Review of Economic Evaluations of New Drugs Based on the Similar Drug Comparison Method in Japan: Did Cost-Effectiveness Results Justify Premiums?

HC3: The Process of Updating the Items of National Health Insurance Benefits Schedule in Taiwan: Is It Fair and Legitimate?

HC4: Tapping Into the Asian Pharmaceutical Market: Global Firms Go Local?

RESEARCH ON METHODS STUDIES South Lounge (3rd Floor)
ME1: Comparison of the Measurement Properties Between the 5-Level EuroQol Group’s 5-Dimension (EQ-5D-5L) Questionnaire and the Functional Assessment of Cancer Therapy – Breast (FACT-B) in Asian Breast Cancer Patients

ME2: Validation of the Kidney Disease and Quality of Life Questionnaire (KDQOL-36) in Haemodialysis Patients in Singapore
ISPOR 5th ASIA-PACIFIC CONFERENCE
2-4 September 2012 ■ Taipei, Taiwan

CONFERENCE AT-A-GLANCE

4:15PM-5:45PM  RESEARCH PODIUMS – I

ME3: Censor Adjusted Net Monetary Benefit of Anti-HCV Therapy in the Variety of Real-World Treatment Setting
ME4: Using Discrete Choice Experiments to Value Health States for Economic Evaluation – The SF-6D in Australia

6:00PM-7:00PM  RESEARCH PODIUMS – II

CLINICAL OUTCOMES STUDIES  Room 105 (1st Floor)
CL1: A Novel Method for Calculating Prevalence of Multiple Sclerosis in Australia
CL2: Usefulness of Days Lost Due to Disability as a New Method in Measuring Burden of Adverse Drug Reactions
CL3: Anticoagulation Control of a Pharmacist Managed Anticoagulation Clinic in a National Referral Centre in Malaysia
CL4: Drug Switching Events Among Users of NSAIDS With or Without Gastro-Protective Drugs as an Early Determinant of Dissatisfaction from Gastrointestinal Adverse Events

CARDIOVASCULAR DISORDERS OUTCOMES STUDIES  North Lounge (3rd Floor)
CV1: Statin Prescription in Australia: A Comparison of Differences in Prescribed Doses and Potential Impact on Health Outcomes
CV2: Age, Dementia, and Evidence-Based Medication Use After Admission for Acute Coronary Syndrome
CV3: Real-World Characterization of Hypertension Patients in Japan: A 1-Year Overview
CV4: Association Between Knowledge and Health Related Quality of Life? Is Patient Education Always Beneficial?

HEALTH CARE EXPENDITURES STUDIES  Room 103 (1st Floor)
EX1: The Effects of Polypharmacy on Health Care Costs and Hospital Admissions in Thai Elderly Population: Multivariate Two-Part Models
EX2: An Observation on the Trend of Outpatient Clinic Utilization and Numbers of Medical Prescription Given in Taiwan Elderly Between 1997 and 2010
EX4: Recent Trends in Community Pharmacy Payment of National Health Insurance in South Korea

HEALTH TECHNOLOGY ASSESSMENT STUDIES  Room 101 (1st Floor)
HT1: Withdrawing
HT2: Withdrawing
HT3: Development of a Check List for Quality Assessment of Pharmacoeconomic Evaluations Submitted for Reimbursement in Taiwan
HT4: Health Technology Assessment Map in Asia – Regional Versus International Influences

PREFERENCE-BASED OUTCOMES STUDIES  South Lounge (3rd Floor)
PR1: Does Medication Adherence Contribute With Health-Related Quality of Life? Findings From a Descriptive Analysis
PR2: A Feasibility Study of Preference-Based Health-Related Quality of Life Measures on Patients With Irritable Bowel Syndrome in Taiwan
PR3: Utility Values for Chemotherapy-Related Adverse Events: A Review of the Literature
PR4: The Effect of Neuropathic Pain on Health Status, Work Productivity Loss, and Health Care Resource Use in Japan

7:00PM-8:30PM  POSTER AUTHOR DISCUSSION HOUR – I

7:00PM-8:30PM  RESEARCH POSTERS & EXHIBITORS’ RECEPTION  Room 201 (2nd Floor)

8:30PM-10:00PM  ASIA CONSORTIUM RECEPTION  Jade (2nd Floor)
All attendees welcome!

TUESDAY, 4 SEPTEMBER

8:30AM-5:00PM  RESEARCH POSTERS – II  Room 201 (2nd Floor)

8:30AM-10:00AM  WELCOME & THIRD PLENARY SESSION  Room 101 (1st Floor)
Chinese/English translation
Challenges of Adopting New Innovative Technologies in Health Care Coverage Decision-Making in Asia

10:00AM-10:15AM  BREAK, EXHIBITS & RESEARCH POSTERS – II

10:15AM-11:15AM  ISSUE PANELS & WORKSHOPS – II
IP2: Personalized Medicine: How Can We Go With It?  Room 101 (1st Floor)
IP3: Challenges in Implementing the 4th Irurdle in China  Room 103 (1st Floor)
WS5: Switch Effect Analysis for Retrospective Comparative Effectiveness Research  Room 105 (1st Floor)
WS6: Evaluating Evidence for Medical Devices – International Experiences  North Lounge (3rd Floor)
W7: Realities of Populating Global Models in Asia  South Lounge (3rd Floor)

11:15AM-12:15PM  POSTER AUTHOR DISCUSSION HOUR – II  Room 201 (2nd Floor)

11:45AM-2:45PM  LUNCH, EXHIBITS & RESEARCH POSTERS – II

12:15PM-1:15PM  EDUCATIONAL SYMPOSIUM  Room 101 (1st Floor)
Targeted Therapies – Are We Ready? Challenges and Pitfalls for Sponsors and Decision-Makers Alike  Sponsored by OptumInsight

1:30PM-2:30PM  EDUCATIONAL SYMPOSIUM  Room 101 (1st Floor)
Understanding Asia’s Payer’s Perspective on Acute Coronary Syndrome

2:45PM-3:45PM  ISSUE PANELS & WORKSHOPS – III
IP4: Using Mapped EQ-5D From Disease-Specific Measures in Cost-Utility Analysis: What is the Current State in Asia Pacific?  Room 105 (1st Floor)
WB: One Size Fits All? Adapting Global Models for Local Needs  Room 103 (1st Floor)
WS9: Equity in Pricing and Reimbursement Decision Across Asia Pacific Countries  Room 101 (1st Floor)
W10: Factors Associated With Pharmaceutical Reimbursement Outcome in Australia: Review of Appraisals of Manufacturers’ Submissions Since 2005  North Lounge (3rd Floor)
W11: Tricks and Traps in Assessing Patient Compliance Using Prescription Claims Databases  South Lounge (3rd Floor)

3:45PM-4:00PM  BREAK, EXHIBITS & RESEARCH POSTERS – II

4:00PM-5:00PM  ISSUE PANELS & WORKSHOPS – IV
IP5: Does Price Discrimination Have a Place in Pharmaceutical Pricing in Asia?  Room 101 (1st Floor)
W12: Decision Making in Health Technology Assessment  Room 103 (1st Floor)
W13: Government and Industry Partnerships for Korean Pharmaceutical Policy: Good Practice Review  Room 105 (1st Floor)
W14: Challenges and Lessons for Establishing Pricing Regulations in Asian Pacific Countries  North Lounge (3rd Floor)
W15: Conducting Real-World Studies in Emerging Asian Markets  South Lounge (3rd Floor)

5:15PM-6:00PM  ISPOR SERVICE & RESEARCH AWARDS PRESENTATION, ISPOR 6th ASIA-PACIFIC CONFERENCE ANNOUNCEMENT & CLOSING REMARKS  Room 101 (1st Floor)
Chinese/English translation
ISPOR Distinguished Service Awards Presentation
ISPOR Research Awards Presentation
ISPOR 6th Asia-Pacific Conference Announcement
CLOSING REMARKS

ISPOR Registration Hours:
Sunday, 2 September  7:00AM-5:00PM
Monday, 3 September  8:00AM-6:00PM
Tuesday, 4 September  8:00AM-6:00PM